Optimizing meropenem administration in ICU patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study investigates whether administering the antibiotic meropenem as 1 gram in 15-minute infusions six times daily can achieve similar serum concentrations as the standard 2 grams in 3-hour infusions three times daily. The study focuses on patients in the intensive care unit (ICU) who require intravenous access for treatment of serious infections. By comparing these two dosing regimens, the researchers aim to determine if shorter, more frequent infusions can maintain effective drug levels while potentially increasing the availability of intravenous access. The study will also monitor patient outcomes, including hospital stay duration and 30-day mortality rates.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients ≥ 18 years admitted to the ICU at Oslo University Hospital, Rikshospitalet and
2. who shall be treated with meropenem because of proven or suspected serious infection and
3. who give their written informed consent either directly or through next of kin

Exclusion Criteria: Patients

1. with known hypersensistivity to betalactam antibiotics or
2. who use of valproat or
3. who are pregnant or
4. the lack of consent.

Where it's running

• Oslo University Hospital
  Oslo, Norway Recruiting

Study contacts

• Principal investigator: Ingvild Nordøy, PhD — Oslo University Hospital
• Study coordinator: Ingvild Nordøy, PhD
• Email: inordoy@ous-hf.no
• Phone: +4793028084

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Xiqing plus probiotics to improve gut balance and drug effects in chronic kidney disease

  This trial will test whether adding Xiqing and probiotics helps lower nitrogen waste and improve drug effectiveness in adults with stage 3–5 chronic kidney disease who are not on dialysis.

  Recruiting Phase 4 Tongji Hospital · Wuhan, Hubei · NCT07182942

• GLP-1 drug effects on muscle and bone during weight loss

  It tests whether GLP-1–based weight-loss medication (tirzepatide) plus a lifestyle program changes muscle and bone in adults 18–50 with obesity (BMI 30–40).

  Recruiting Phase 4 Pennington Biomedical Research Center · Baton Rouge, Louisiana and 1 other locations · NCT07154719

• Tenecteplase versus alteplase before mechanical thrombectomy for acute large-vessel ischemic stroke

  This trial tests whether tenecteplase given before mechanical thrombectomy helps adults with acute large-vessel ischemic stroke within 4.5 hours recover better than standard alteplase.

  Recruiting Phase 3 Xuanwu Hospital, Beijing · Beijing, Beijing Municipality · NCT06658197

• Comparing morning versus bedtime aspirin for cardiovascular health

  This study is testing if taking aspirin at bedtime works better than taking it in the morning for people who are already using aspirin to protect their heart health.

  Recruiting Phase 4 Herlev and Gentofte Hospital · Hellerup · NCT05932472

• Observing genetic factors in Indian children with leukemia

  This study looks at how genetic differences might affect side effects from chemotherapy in Indian children with leukemia to see how it impacts their quality of life.

  Recruiting at 2 sites University of Geneva, Switzerland · New Delhi and 1 other locations · NCT05512169

• Measuring drug levels in children on ECMO support

  This study is trying to see how well certain sedatives and pain medications work in children on ECMO support to improve their care.

  Recruiting Boston Children's Hospital · Boston, Massachusetts · NCT03593408

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.